Buy & Sell Ryanair Holdings plc (RYAAY) – Ryanair Holdings plc Price Today
Key Stats
- $32.13BMarket Cap
- IndustrialsSector
- -17.07%3M Drawdown
- $29.80BEnterprise Value
- 1.53%Dividend Yield
- 67 daysTypical Hold Time
Ryanair Holdings plc (RYAAY) is currently valued at a market capitalization of $32.13B, with an enterprise value of $29.80B. Over the past 52 weeks, Ryanair Holdings plc has traded between a low of $53.24 and a high of $73.82, highlighting its annual price range. Over the past three months, Ryanair Holdings plc has recorded a drawdown of -17.07%, reflecting recent price volatility. Ryanair Holdings plc offers a dividend yield of 1.53%, with the most recent dividend of $0.45 paid on 16 Jan 26. On average, investors hold Ryanair Holdings plc for approximately 67 days, indicating typical investor behavior on the platform.
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Most Recent News
Supreme Court rules government geofence data collection is a Fourth Amendment search.
The U.S. Supreme Court ruled in Chatrie v. U.S. that government collection of location data via geofence warrants constitutes a search under the Fourth Amendment. This decision overturns a lower court ruling and requires further review of whether the...
DBV Technologies plans BLA submission for VIASKIN® Peanut patch in kids 4-7 after FDA collaboration.
DBV Technologies is preparing to submit a Biologics License Application (BLA) for its VIASKIN® Peanut patch aimed at children aged 4 to 7 years. The company has engaged in detailed discussions with the FDA to ensure a thorough and efficient review pr...
FDA approves ZORYVE cream for treating plaque psoriasis in children as young as 2 years old
The FDA has approved Arcutis Biotherapeutics' ZORYVE cream 0.3% for treating plaque psoriasis in children aged 2 and older. This once-daily, non-steroidal topical treatment is safe, effective, and can be used on sensitive skin areas without duration ...